210 related articles for article (PubMed ID: 26125136)
1. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.
Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y
AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136
[TBL] [Abstract][Full Text] [Related]
2. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
3. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
4. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
6. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
7. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
8. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
[TBL] [Abstract][Full Text] [Related]
9. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
[TBL] [Abstract][Full Text] [Related]
10. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
[TBL] [Abstract][Full Text] [Related]
11. Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.
Kesavardhana S; Varadarajan R
J Virol; 2014 Sep; 88(17):9590-604. PubMed ID: 24920800
[TBL] [Abstract][Full Text] [Related]
12. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S
J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
14. A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.
Su S; Wang Q; Xu W; Yu F; Hua C; Zhu Y; Jiang S; Lu L
AIDS; 2017 Apr; 31(7):885-894. PubMed ID: 28121713
[TBL] [Abstract][Full Text] [Related]
15. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors.
Li J; Chen X; Huang J; Jiang S; Chen YH
Immunobiology; 2009; 214(1):51-60. PubMed ID: 19159827
[TBL] [Abstract][Full Text] [Related]
16. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
Chong H; Qiu Z; Su Y; Yang L; He Y
AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
[TBL] [Abstract][Full Text] [Related]
17. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
19. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
20. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
